Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy?
Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy?
复制标题
DOI：
10.1097/01.mib.0000437616.37000.41
复制
发表时间：
2014-03
影响因子：
4.9
通讯作者：
Durum SK
中科院分区：
文献类型：
--
作者：
McLean MH;Neurath MF;Durum SK
在西方世界，炎症性肠病是患者发病率较高的原因。有几种免疫抑制疗法可用，但与潜在的显着不良反应有关。此外，仍有一批难治性或复发性疾病患者。因此，寻找新的治疗剂的工作仍在继续。在这篇综述中，我们评估了一些指定的细胞因子在炎症性肠病发病机制中的作用，并讨论了它们的操作如何被探索为该疾病的治疗策略。选择用于讨论的白介素类(ILs)反映了目前最有希望成为未来治疗靶点的那些，以及讨论了一些最近发现的ILs在这方面的作用，如IL-27、IL-33、IL-35和IL-22。
Inflammatory bowel disease accounts for significant patient morbidity in the Western world. Several immunosuppressive therapies are available but are associated with potential significant adverse effects. In addition, there remains a cohort of patients with refractory or relapsing disease. Therefore, the search for novel therapeutic agents continues. In this review, we evaluate the role of a number of designated cytokines that are candidates in the pathogenesis of inflammatory bowel disease and discuss how their manipulation has been explored as a therapeutic strategy for this disease. The interleukins (ILs) chosen for discussion reflect those that currently show most promise as future therapeutic targets, as well as discussing the role of some of the most recently identified ILs, such as IL-27, IL-33, IL-35, and IL-22, in this context.